Logotype for Roche Holding AG

Roche (ROG) H1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Roche Holding AG

H1 2026 earnings summary

22 Oct, 2026

Executive summary

  • H1 sales rose 6% at CER to CHF 30,364m, but fell 2% in CHF as Swiss franc appreciation weighed on reported results.

  • Core operating profit increased 10% at CER and Core EPS rose 9%; both Pharma and Diagnostics grew at CER.

  • Five FDA Priority Reviews and positive phase III results marked strong pipeline progress.

Financial highlights

  • Core operating profit was CHF 11,856m, up 10% at CER; Core EPS was CHF 10.85, up 9% at CER. Both declined in CHF, by 1% and 2%, respectively.

  • IFRS net income was CHF 7,325m, down 6% in CHF but up 6% at CER; Core net income rose 11% at CER.

  • Operating free cash flow reached CHF 6,264m, up 21% at CER; free cash flow was CHF 4,197m, up 58% at CER and 26% in CHF.

  • IFRS operating profit was CHF 9,671m, down 6% in CHF and up 6% at CER; non-core operating items totaled CHF 2,185m.

Outlook and guidance

  • 2026 guidance confirmed: mid-single-digit sales growth and high-single-digit Core EPS growth at CER.

  • Expected 2026 LOE impact is ~CHF 0.6bn, including losses of Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra.

  • Further dividend growth in Swiss francs expected; significant pipeline readouts include Itovebi, Lunsumio, sefaxersen and obesity programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Roche